Burning mouth syndrome in Parkinson’s disease: dopamine as cure or cause?
Open Access
- 10 February 2012
- journal article
- case report
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 13 (3) , 255-257
Abstract
Burning mouth syndrome has been reported as being more common in Parkinson’s disease patients than the general population. While the pathophysiology is unclear, decreased dopamine levels and dopamine dysregulation are hypothesized to play a role. We report a patient with Parkinson’s disease who developed burning mouth syndrome with carbidopa/levodopa. Our patient had resolution of burning mouth symptoms when carbidopa/levodopa was replaced with a dopamine agonist. Based on our patient’s clinical course, in conjunction with earlier studies assessing the relationship between burning mouth syndrome and Parkinson’s disease, we discuss a potential role for dopamine in burning mouth syndrome in Parkinson’s disease.Keywords
This publication has 10 references indexed in Scilit:
- Pathophysiology of primary burning mouth syndromeClinical Neurophysiology, 2012
- Pain in Parkinson's diseaseMovement Disorders, 2010
- Pain in Parkinson’s disease: Prevalence and characteristicsPain, 2009
- Burning mouth syndrome responsive to pramipexolThe Journal of Headache and Pain, 2008
- Delayed l-DOPA-induced hyperalgesiaPharmacology Biochemistry and Behavior, 2006
- Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndromeThe Lancet Neurology, 2006
- Dopamine responsiveness is regulated by targeted sorting of D2 receptorsProceedings of the National Academy of Sciences, 2005
- Striatal dopamine D1 and D2 receptors in burning mouth syndromePain, 2003
- Role of the dopaminergic system in chronic pain – a fluorodopa-PET studyPain, 2001
- Burning mouth in Parkinson's Disease sufferersGerodontology, 1998